{
    "code": "60000961",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60000961",
    "time": "2021-08-06 03:12:06",
    "許可證字號": "衛部菌疫輸字第000961號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "113\/07\/18",
    "發證日期": "103\/07\/18",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA06000096109",
    "中文品名": "賀癌平 凍晶注射劑440毫克",
    "英文品名": "Herceptin Vial 440mg",
    "適應症": "Herceptin應使用於下列HER2過度表現或HER2基因amplification之早期乳癌、轉移性乳癌患者：\r\n1.早期乳癌(EBC)：\r\n  (1)經外科手術、化學療法(術前或術後)之輔助療法。\r\n  (2)以doxorubicin與cyclophosphamide治療，再合併paclitaxel或docetaxel之輔助療法。\r\n  (3)與docetaxel及carboplatin併用之輔助療法。\r\n  (4)術前與化學療法併用和術後之輔助療法使用於治療局部晚期(包括炎症)乳癌或腫瘤(直徑>2厘米)\r\n\r\n2.轉移性乳癌(MBC)\r\n  (1)單獨使用於曾接受過一次(含)以上化學療法之轉移性乳癌；除非患者不適合使用anthracycline或taxane，否則先前之化學治療應至少包括anthracycline或taxane。\r\n     使用於荷爾蒙療法失敗之荷爾蒙受體陽性之患者，除非患者不適用荷爾蒙療法。\r\n  (2)與paclitaxel或docetaxel併用於未曾接受過化學療法之轉移性乳癌。\r\n  (3)與芳香環酶抑制劑併用於荷爾蒙受體陽性之轉移性乳癌。\r\n\r\n3.轉移性胃癌(MGC)\r\n  Herceptin合併capecitabine(或5-fluorouracil)及cisplatin適用於未曾接受過化學治療之HER2過度表現轉移性胃腺癌(或胃食道接合處腺癌)的治療。",
    "劑型": "243凍晶注射劑",
    "包裝": "玻璃小瓶裝附溶劑20毫升裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "TRASTUZUMAB",
    "限制項目": "02輸　入",
    "申請商名稱": "1901701100  羅氏大藥廠股份有限公司",
    "申請商地址": "台北市信義區松仁路100號40樓、40樓之1、41樓之1",
    "主製造廠": [
        {
            "製造廠名稱": "FUS0767100  GENENTECH INC.",
            "製造廠廠址": "4625 NE BROOKWOOD PARKWAY, HILLSBORO OREGON, 97124 USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FCH0257000  F. HOFFMANN-LA ROCHE LTD.",
            "製造廠廠址": "WURMISWEG, CH-4303 KAISERAUGST, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "包裝廠及溶劑廠"
        },
        {
            "製造廠名稱": "FSG0030000  Roche Singapore Technical Operations Pte.Ltd.",
            "製造廠廠址": "10 Tuas Bay Link, 637394 Singapore",
            "製造廠公司地址": "",
            "製造廠國別": "SINGAPORE",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "FSG0032000  Lonza Biologics Tuas Pte Ltd.",
            "製造廠廠址": "35 Tuas South Avenue 6, Singapore, 637377",
            "製造廠公司地址": "",
            "製造廠國別": "SINGAPORE",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "FUS0326000  MADE BY GENENTECH INC. MADE FOR F. HOFFMANN-LA ROCHE LTD.",
            "製造廠廠址": "1 DNA WAY SOUTH SAN FRANCISCO CA 94080, U.S.A.",
            "製造廠公司地址": "CH-4070 BASEL, SWITZERLAND",
            "製造廠國別": "UNITED STATES",
            "製程": ""
        },
        {
            "製造廠名稱": "FUS0767000  GENENTECH, INC.",
            "製造廠廠址": "1000 NEW HORIZONS WAY, VACAVILLE, CA 95688, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000500",
            "成分名稱": "TRASTUZUMAB",
            "含量描述": "",
            "含量": "440.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Herceptin 440mg HTO_Vial+Solvent-104-09-30(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000961&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "Herceptin IV_CDS21.0_0321-HER-01(450x500mm)_typesetting-110-04-19.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000961&Seq=010&Type=9"
        },
        {
            "title": "Solvent Label-108-04-25(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000961&Seq=008&Type=8"
        },
        {
            "title": "Herceptin 440mg ex SSF_Label-108-04-25(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000961&Seq=007&Type=8"
        },
        {
            "title": "Herceptin 440mg ex HTO_Label-108-04-25(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000961&Seq=006&Type=8"
        },
        {
            "title": "Herceptin 440mg ex SSF_Carton-108-04-25(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000961&Seq=005&Type=8"
        },
        {
            "title": "Herceptin 440mg ex HTO_Carton-108-04-25(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000961&Seq=004&Type=8"
        },
        {
            "title": "Herceptin IV 440mg_HTO_外盒(新地址)-108-02-21(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000961&Seq=003&Type=8"
        },
        {
            "title": "100009610004_Sticker-103-08-18.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000961&Seq=002&Type=8"
        }
    ]
}